Skip to main content

Tweets

Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/luxDDluddM

TheDaoIndex @KDAO2011 ( View Tweet )

3 years 8 months ago
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line. 1/2 switch JAKi->TNFi 1/3 switch JAKi ->JAKi Why high proportion of JAKi cycling, when AE reason for switch low? https://t.co/APdWW7fzJE Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE 13 studies included: 70% with low risk of bias BEL improved clinical response at W52 vs non-users OR 1.44 Decrease risk of severe cutaneous flare OR 0.51 Most studies against placebo group @RheumNow https://t.co/2bSwNKRHZZ
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
TCZ in GCA: what does it mean for diabetes? post-hoc GiACTA: HbA1c obvs better with TCZ (PNL dosing) but then: even after adjusting for PNL dose, apparent benefit Is there protective effect? Interesting observation worth investigating ABST0461 @MGHrheumatology #ACR22 @RheumNow https://t.co/CF1as5y7Yy
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
#ACR22 Yr in Review. John Varga says novel vaccination immune therapy may reverse #fibrosis - at least in mice. Hope for #scleroderma & other fibrotic diseases. Data need to be transferred into human experiments @RheumNow https://t.co/ybFRXheQq3
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH 7.3% had "severe non-adherence" by HCQ levels Hazard ratio of flare 3.3, damage 4.26, and death 5.4 Not surprising, but very useful for pt discussion Checking HCQ levels are helpful! @Rheumnow https://t.co/S7P9oTPRGJ
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Study showing Evusheld can protect our patients who are immunosuppressed; it saved alot of live. One of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/6ekWvA6Ruw

TheDaoIndex @KDAO2011 ( View Tweet )

3 years 8 months ago
ACR Year in review J. Varga What drives TNF superproduction in RA? Study mice 🐁 model grafted w/ human synovial tissue suggests important role of mitochondrial stress through aspartate deficiency A potential new therapeutic target 🎯 RA? @RheumNow #ACR22 #ACRyearinreview https://t.co/lKrOn05sFp
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Was delighted to be a (very) small part of the fantastic work by the covid GRA getting a special mention by Dr Langford at yr in review #ACR22 @RheumNow Congrats @RichardPAConway @EBRheum @jeffsparks @SattuiSEMD @rheum_cat 🎉 https://t.co/W0n7rW9pma
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
×